+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Leiomyoma Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767702
  • Report
  • 165 pages
  • VPA Research
UP TO OFF
until Sep 30th 2019
1 of 3

FEATURED COMPANIES

  • Abbott Laboratories
  • AbbVie Inc
  • Bayer AG
  • ICON Plc
  • ObsEva SA
  • Pfizer Inc
  • MORE
The global clinical trial report- “2019 Leiomyoma Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Leiomyoma. It presents in-depth analysis of Leiomyoma clinical trials across markets and companies. The research work is for providing complete understanding into trends in Leiomyoma.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Leiomyoma clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Leiomyoma

The research work is prepared through extensive and continuous research on Leiomyoma trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Leiomyoma patients are identified
  • The report includes panorama of Leiomyoma clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Leiomyoma clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbott Laboratories
  • AbbVie Inc
  • Bayer AG
  • ICON Plc
  • ObsEva SA
  • Pfizer Inc
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Leiomyoma Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Leiomyoma Clinical Trials by Region
2.2.2 Average Enrollment of Leiomyoma Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Leiomyoma Treatment, 2019

3. Region wise Leiomyoma Clinical Trials
3.1 Asia Pacific Leiomyoma Clinical Trials by Country
3.2 Europe Leiomyoma Clinical Trials by Country
3.3 North America Leiomyoma Clinical Trials by Country
3.4 Middle East and Africa Leiomyoma Clinical Trials by Country
3.5 South and Central America Leiomyoma Clinical Trials by Country

4. Leiomyoma Clinical Trial Trends
4.1 Start Year wise Leiomyoma Clinical Trials
4.2 Phase wise Leiomyoma Clinical Trials
4.3 Trial Status wise Leiomyoma Clinical Trials
4.4 Trial Type wise Leiomyoma Clinical Trials

5. Leiomyoma Average Enrollment Trends
5.1 Average Enrollment in Leiomyoma Trials by Year
5.2 Average Enrollment in Leiomyoma Trials by Phase
5.3 Average Enrollment in Leiomyoma Trials by Status
5.4 Average Enrollment in Leiomyoma Trials by Type of Trial

6. Companies Participating in Leiomyoma Clinical Trials
6.1 Leiomyoma Trials by Sponsor Type
6.2 Leiomyoma Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Leiomyoma Trials- Phase 1
7.2 Leiomyoma Trials- Phase 2
7.3 Leiomyoma Trials- Phase 3
7.4 Leiomyoma Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Leiomyoma Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Leiomyoma Clinical Trials and Enrolment
Figure 5: Europe - Country wise Leiomyoma Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Leiomyoma Clinical Trials and Enrolment
Figure 7: North America - Country wise Leiomyoma Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Leiomyoma Clinical Trials and Enrolment
Figure 9: Leiomyoma Clinical Trials by Phase
Figure 10: Leiomyoma Clinical Trials by Trial Status
Figure 11: Leiomyoma Clinical Trials by Type
Figure 12: Leiomyoma Clinical Trials by Sponsor Type
Figure 13: Leiomyoma Clinical Trials by Leading Sponsors
Figure 14: Leiomyoma Average Enrollment by Phase
Figure 15: Leiomyoma Average Enrollment by Trial Status
Figure 16: Leiomyoma Average Enrollment by Type
Figure 17: Leiomyoma- Average Enrolment by Type of Sponsors
Figure 18: Leiomyoma- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Leiomyoma Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Leiomyoma Clinical Trials and Enrolment
Table 5: Europe - Country wise Leiomyoma Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Leiomyoma Clinical Trials and Enrolment
Table 7: North America - Country wise Leiomyoma Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Leiomyoma Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Leiomyoma Average Enrollment by Phase
Table 15: Leiomyoma Average Enrollment by Trial Status
Table 16: Leiomyoma Average Enrollment by Type
Table 17: Leiomyoma- Average Enrolment by Type of Sponsors
Table 18: Leiomyoma- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abbott Laboratories
  • AbbVie Inc
  • Bayer AG
  • ICON Plc
  • Neurocrine Biosciences Inc
  • ObsEva SA
  • Pfizer Inc
  • Repros Therapeutics Inc
  • Richter Gedeon Nyrt
  • Takeda Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll